SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Antman KH, Pass HI, Li FP et al. Benign and malignant mesothelioma, cancer. In: De Vita VT Jr, HellmanS, RosenbergSA (ed). Cancer: Principles and Practice of Oncology, 4th edn. Lippincott Williams & Wilkins, Philadelphia, 1993; 1489508.
  • 2
    Antman KH. Natural history and epidemiology of malignant mesothelioma. Chest 1993; 103: 373S.
  • 3
    Pisani RJ, Colby TV, Williams DE. Malignant mesothelioma of the pleura. Mayo Clin. Proc. 1988; 63: 123444.
  • 4
    Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345: 5359.
  • 5
    Hansen J, De Klerk NH, Musk AW, Hobbs MST. Environmental exposure to crocidolite and mesothelioma. Exposure-response relationships. Am. J. Respir. Crit. Care Med. 1998; 157: 6975.
  • 6
    Metintas M, Ozdemir N, Hillerdal G et al. Environmental asbestos exposure and malignant pleural mesothelioma. Respir. Med. 1999; 93: 34955.
  • 7
    Metintas S, Metintas M, Ucgun I, Oner U. Malignant mesothelioma due to environmental exposure to asbestos: follow-up of a Turkish cohort living in a rural area. Chest 2002; 122: 2224.
  • 8
    Senyigit A, Babayigit C, Gokirmak M et al. Incidence of malignant pleural mesothelioma due to environmental asbestos fiber exposure in the southeast of Turkey. Respiration 2000; 67: 61014.
  • 9
    Senyigit A, Bayram H, Babayigit C et al. Malignant pleural mesothelioma caused by environmental exposure to asbestos in the southeast of Turkey: CT findings in 117 patients. Respiration 2000; 67: 61522.
  • 10
    De Luca A, Baldi A, Esposito V et al. The retinoblastoma gene family pRb/p105, p107, pRb2/p130 and simian virus−40 large T–antigen in human mesotheliomas. Nat. Med. 1997; 3: 91316.
  • 11
    McLaren BR, Haenel T, Stevenson S et al. Simian virus (SV) 40 like sequences in cell lines and tumour biopsies from Australian malignant mesotheliomas In Process Citation. Aust. NZ. J. Med. 2000; 30: 4506.
  • 12
    Pass HI, Donington JS, Wu P et al. Human mesotheliomas contain the simian virus-40 regulatory region and large tumour antigen DNA sequences. J. Thorac. Cardiovasc. Surg. 1998; 116: 8549.
  • 13
    Ramael M, Nagels J, Heylen H et al. Detection of SV40 like viral DNA and viral antigens in malignant pleural mesothelioma. Eur. Respir. J. 1999; 14: 13816.
  • 14
    Pilatte Y, Vivo C, Renier A et al. Absence of SV40 large T-antigen expression in human mesothelioma cell lines. Am. J. Respir. Cell. Mol. Biol. 2000; 23: 78893.
  • 15
    Gazdar AF, Carbone M. Molecular pathogenesis of malignant mesothelioma and its relationship to simian virus 40. Clin. Lung Cancer 2003; 5: 17781.
  • 16
    Neugut AI, Ahsan H, Antman KH. Incidence of malignant mesothelioma after thoracic radiotherapy. Cancer 1997; 80: 94850.
  • 17
    Hillerdal G. Malignant mesothelioma 1982. Review of 4710 published cases. Brit. J. Dis. Chest 1983; 77: 32143.
  • 18
    Grove A, Paulsen SM, Gregersen M. The value of immunohistochemistry of pleural biopsy specimens in the differential diagnosis between malignant mesothelioma and metastatic carcinoma. Pathol. Res. Pract. 1994; 190: 104455.
  • 19
    Wick MR, Loy T, Mills SE et al. Malignant epithelial pleural mesothelioma versus peripheral pulmonary adenocarcinoma: a histochemical, ultrastructural and immunohistologic study of 103 cases. Hum. Pathol. 1990; 21: 75966.
  • 20
    Zeng L, Fleury-Feith J, Monnet I et al. Immunocytochemical characterization of cell lines from human malignant mesothelioma. Hum. Pathol. 1994; 25: 22734.
  • 21
    Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. Mod. Pathol. 1998; 11: 92933.
  • 22
    Chieng DC, Yee H, Schaefer D et al. Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions. Cancer 2000; 90: 194200.
  • 23
    Kitazume H, Kitamura K, Mukai K et al. Cytologic differential diagnosis among reactive mesothelial cells, malignant mesothelioma, and adenocarcinoma: utility of combined E-cadherin and calretinin immunostaining. Cancer 2000; 90: 5560.
  • 24
    Amin KM, Litzky LA, Smythe WR et al. Wilms’ tumor 1 susceptibility (WT1) gene products are selectively epressed in malignant mesothelioma. Am. J. Pathol. 1995; 146: 34456.
  • 25
    Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2–40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma. Mod. Pathol. 2005; 18: 10510.
  • 26
    Brown RW, Clark GM, Tandon AK, Allred DC. Multiple-marker immunohistochemical phenotypes distinguishing malignant pleural mesothelioma from pulmonary adenocarcinoma. Hum. Pathol. 1993; 24: 34754.
  • 27
    Ordonez NG. The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelial mesothelioma and lung adenocarcinoma. Am. J. Surg. Pathol. 2003; 27: 103151.
  • 28
    Testa JR, Pass HI, Carbone M. Benign and malignant mesothelioma. In: De Vita VT Jr, HellmanS, RosenbergSA (ed). Cancer: Principles and Practice of Oncology, 6th edn. Lippincott Williams & Wilkins, Philadelphia, 2001; 1937.
  • 29
    Robinson BW, Creaney J, Lake R et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003; 362: 161216.
  • 30
    British Thoracic Society Standards of Care Committee. Statement on malignant mesothelioma in the United Kingdom. Thorax 2001; 56: 250.
  • 31
    Hwang HC, Smythe WR, Elshami AA et al. Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am. J. Respir. Cell. Mol. Biol. 1995; 13: 716.
  • 32
    Heelan RT, Rusch VW, Begg CB et al. Staging of malignant pleural mesothelioma: comparison of CT and MR imaging. AJR. Am. J. Roentgenol. 1999; 172: 103947.
  • 33
    Marom EM, Erasmus JJ, Pass HI, Patz EF Jr. The role of imaging in malignant pleural mesothelioma. Semin. Oncol. 2002; 29: 2635.
  • 34
    Patz EF Jr, Shaffer K, Piwnica-Worms DR et al. Malignant pleural mesothelioma: value of CT and MR imaging in predicting resectability. AJR. Am. J. Roentgenol. 1992; 159: 9616.
  • 35
    Miller WT Jr, Gefter WB, Miller WT Sr. Asbestos-related chest diseases: plain radiographic findings. Semin. Roentgenol. 1992; 27: 10220.
  • 36
    Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: who benefits? Chest 1995; 107: 345S350S.
  • 37
    Benard F, Sterman D, Smith RJ et al. Metabolic imaging of malignant pleural mesothelioma with fluorodeoxyglucose positron emission tomography. Chest 1998; 114: 71322.
  • 38
    Flores RM, Akhurst T, Gones M et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2003; 126: 11.
  • 39
    Gerbaudo VH, Britz-Cunningham S, Sugarbaker DJ, Treves ST. Metabolic significance of the pattern, intensity and kinetics of 18F-FDG uptake in malignant pleural mesothelioma. Thorax 2003; 58: 107782.
  • 40
    Schneider DB, Clary-Macy C, Challa S et al. Positron emission tomography with f18-fluorodeoxyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2000; 120: 12833.
  • 41
    Butchart EG, Ashcroft T, Barnsley WC et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura: experience with 29 patients. Thorax 1976; 31: 1524.
  • 42
    Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995; 108: 11228.
  • 43
    Antman KH. Malignant mesothelioma: prognostic variables in a registry of 180 patients. The Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965–1985. J. Clin. Oncol. 1988; 6: 147.
  • 44
    Curran D, Sahmoud T, Therasse P et al. Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience. J. Clin. Oncol. 1998; 16: 14552.
  • 45
    Edwards JG, Abrams KR, Leverment JN et al. Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 2000; 55: 7315.
  • 46
    Herndon JE, Green MR, Chahinian AP et al. Factors predictive of survival survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998; 113: 72331.
  • 47
    Mikulski SM, Costanzi JJ, Vogelzang NJ et al. Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J. Clin. Oncol. 2002; 20: 27481.
  • 48
    Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 2003 July 15; 21: 263644.
  • 49
    Sugarbaker DJ, Strauss GM, Lynch TJ et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J. Clin. Oncol. 1993; 11: 11728.
  • 50
    Nasreen N, Mohammed KA, Dowling PA, Ward MJ, Galffy G, Antony VB. Talc induces apoptosis in human malignant mesothelioma cells in vitro. Am. J. Resp. Crit. Care Med., 2000; 161 (Part 1): 595600.
  • 51
    Pien GW, Gant M, Washam C, Sterman DH. Use of an implantable pleural catheter for ‘Trapped Lung’ syndrome in patients with malignant pleural effusion. Chest 2001; 119: 16416.
  • 52
    Tsang V, Fernando HC, Goldstraw P. Pleuroperitoneal shunt for recurrent malignant pleural effusions. Thorax 1990; 45: 36972.
  • 53
    Waller DA, Morritt GN, Forty J. Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion. Chest 1995; 107: 14546.
  • 54
    Van Ruth S, Baas P, Zoetmulder FA. Surgical treatment of malignant pleural mesothelioma: a review. Chest 2003; 123: 55161.
  • 55
    Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995; 107: 332S344S.
  • 56
    Lee TT, Everett DL, Shu HK et al. Radical pleurectomy/decortication and intraoperative radiotherapy followed by conformal radiation with or without chemotherapy for malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 2002; 124: 11839.
  • 57
    Rusch VW, Venkatraman ES. Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically. Ann. Thorac. Surg. 1999; 68: 1799804.
  • 58
    Rusch VW. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest 1993; 103: 382S384S.
  • 59
    Sugarbaker DJ, Flores RM, Jaklitsch MT et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J. Thorac. Cardiovasc. Surg. 1999; 117: 5463.
  • 60
    Grondin SC, Sugarbaker DJ. Pleuropneumonectomy in the treatment of malignant pleural mesothelioma. Chest 1999; 116: 450S454S.
  • 61
    Maggi G, Casadi C, Cianci R et al. Trimodality management of malignant pleural mesothelioma. Eur. J. Cardiothorac. Surg. 2001; 19: 346.
  • 62
    Rusch VW, Piantadosi S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. A Lung Cancer Study Group trial. J. Thorac. Cardiovasc. Surg. 1991; 102: 19.
  • 63
    Rusch VW, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 1996; 111: 81525.
  • 64
    Sugarbaker DJ, Heher EC, Lee TH et al. Extrapleural pneumonectomy, chemotherapy and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J. Thorac. Cardiovasc. Surg. 1991; 102: 1014.
  • 65
    Rice TW, Adelstein DJ, Kirby TJ et al. Aggressive multimodality therapy for malignant pleural mesothelioma. Ann. Thorac. Surg. 1994; 58: 249.
  • 66
    Rusch V, Saltz L, Venkatraman E et al. A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J. Clin. Oncol. 1994; 12: 115663.
  • 67
    Rusch VW. Pleurectomy/decortication in the setting of multimodality treatment for diffuse malignant pleural mesothelioma. Semin. Thorac. Cardiovasc. Surg. 1997; 9: 36772.
  • 68
    Moskal TL, Dougherty TJ, Urschel JD et al. Operation and photodynamic therapy for pleural mesothelioma: 6-year follow-up. Ann. Thorac. Surg. 1998; 66: 112833.
  • 69
    Pass HI, Temeck BK, Kranda K et al. Phase III randomized trial of surgery with or without intraoperative photodynamic therapy and postoperative immunochemotherapy for malignant pleural mesothelioma. Ann. Surg. Oncol. 1997; 4: 62833.
  • 70
    Schouwink H, Rutgers ET, Van Der Sijp J et al. Intraoperative photodynamic therapy after pleuropneumonectomy in patients with malignant pleural mesothelioma: dose finding and toxicity results. Chest 2001; 120: 116774.
  • 71
    Baas P, Schouwink H, Zoetmulder FA. Malignant pleural mesothelioma. Ann. Oncol. 1998; 9: 13949.
  • 72
    De Graaf-Strukowska L, Van Der Zee J, Van Putten W, Senan S. Factors influencing the outcome of radiotherapy in malignant mesothelioma of the pleura—a single institution experience with 189 patients. Int. J. Radiat. Oncol. Biol. Phys. 1999; 43: 51116.
  • 73
    Boutin C, Rey F, Viallat JR. Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. Chest 1995; 108: 7548.
  • 74
    Bydder S, Phillips M, Joseph DJ et al. A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Brit. J. Cancer 2004; 91: 910.
  • 75
    Ahamad A, Stevens C, Smythe R et al. Intensity-modulated radiation therapy: a novel approach to the management of malignant pleural mesothelioma. Int. J. Radiat. Oncol. Biol. Phys. 2003; 55: 768.
  • 76
    Ahamad A, Stevens C, Smythe R et al. Promising early local control of malignant pleural mesothelioma following postoperative intensity modulated radiotherapy (IMTR) to the chest. Cancer J. 2003; 9: 476.
  • 77
    Janne PA. Chemotherapy for malignant pleural mesothelioma. Clin. Lung Cancer 2003; 5: 98106.
  • 78
    Favaretto AG, Aversa SM, Paccagnella A et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 2003; 97: 27917.
  • 79
    Sugarbaker DJ, Garcia JP, Richards WG et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma. Results in 120 consecutive patients. Ann. Surg. 1996; 224: 28894.
  • 80
    Baldini EH, DeCamp MM Jr, Katz MS et al. Patterns of recurrence and outcome for patients with clinical stage II non-small-cell lung cancer. Am. J. Clin. Oncol. 1999; 22: 814.
  • 81
    Weder W, Kestenholz P, Taverna C et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J. Clin. Oncol. 2004; 22: 34517.
  • 82
    Stahel RA, Weder W, Ballabeni P et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma: a multicentre phase II trial of the SAKK (Abstract). Proc. Am. Soc. Clin. Oncol. 2004; 23: 626a.
  • 83
    Gordon GJ, Jensen RV, Hsiao LL et al. Using gene expression ratios to predict outcome among patients with mesothelioma. J. Natl. Cancer Inst. 2003; 95: 598605.
  • 84
    Pass HI, Liu Z, Wali A et al. Gene expression profiles predict survival and progression of pleural mesothelioma. Clin. Cancer Res. 2004; 10: 84959.
  • 85
    Ike O, Shimuzu V, Hitomi S et al. Treatment of malignant pleural effusions with doxorubicin hydrochloride-containing ply (1-lactic acid) microspheres. Chest 1991; 99: 911.
  • 86
    Monneuse O, Beaujard AC, Guibert B et al. Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies. Brit. J. Cancer 2003; 88: 183943.
  • 87
    Van Ruth S, Baas P, Haas RL et al. Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann. Surg. Oncol. 2003; 10: 17682.
  • 88
    Robinson BW, Manning LS, Bowman RV et al. The scientific basis for the immunotherapy of human malignant mesothelioma. Eur. Respir. Rev. 1993; 3: 195.
  • 89
    Astoul P, Picat-Joossen D, Viallat JR, Boutin C. Intrapleural administration of interleukin-2 for the treatment of patients with malignant pleural mesothelioma: a phase II study. Cancer 1998; 83: 2099104.
  • 90
    Boutin C, Nussbaum E, Monnet I et al. Intrapleural treatment with recombinant gamma-interferon in early stage malignant mesothelioma. Cancer 1994; 74: 24607.
  • 91
    Boutin C, Viallat JR, Van Zandwijk N et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991; 67: 20337.
  • 92
    Goey SH, Eggermont AM, Punt CJ et al. Intrapleural adminstration of interleukin 2 in pleural mesothelioma: a phase I–II study. Brit. J. Cancer 1995; 72: 12838.
  • 93
    Nowak AK, Lake RA, Kindler HL, Robinson BW. New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. Semin. Oncol. 2002; 29: 8296.
  • 94
    Robinson BW, Mukherjee SA, Davidson A et al. Cytokine gene therapy or infusion as treatment for solid human cancer. J. Immunother. 1998; 21: 21117.
  • 95
    Monnet I, Breau JL, Moro D et al. Intrapleural infusion of activated macrophages and gamma-interferon in malignant pleural mesothelioma: a phase II study. Chest 2002; 121: 19217.
  • 96
    Davidson JA, Musk AW, Wood BR et al. Intralesional cytokine therapy in cancer: a pilot study of GM-CSF infusion in mesothelioma. J. Immunother. 1998; 21: 38998.
  • 97
    Molnar-Kimber KL, Sterman DH, Chang M et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 1998; 9: 212133.
  • 98
    Sterman D, Treat J, Litzky LA et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum. Gene Ther. 1998; 9: 108392.
  • 99
    Mukherjee S, Haenel T, Himbeck R et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Ther. 2000; 7: 66370.
  • 100
    Giuliano M, Catalano A, Strizzi L et al. Adenovirus-mediated wild-type p53 overexpression reverts tumourigenicity of human mesothelioma cells. Int. J. Mol. Med. 2000; 5: 5916.
  • 101
    Procopio A, Marinacci R, Marinetti MR et al. SV40 expression in human neoplastic and non-neoplastic tissues: perspectives on diagnosis, prognosis and therapy of human malignant mesothelioma. Dev. Biol. Stand. 1998; 94: 3617.
  • 102
    Pataer A, Smythe WR, Yu R et al. Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines. J. Thorac. Cardiovasc. Surg. 2001; 121: 617.
  • 103
    Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 1990; 82: 297300.
  • 104
    Mulligan RC. The basic science of gene therapy. Science 1993; 26: 92632.
  • 105
    Vile RG, Nelson JA, Castleden S, Chong H, Hart IR. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res. 1994; 54: 622834.
  • 106
    Schwarzenberger P, Lei DH, Freeman SM et al. Antitumor activity with the HSV-tk-gene-modified cell line PA-1-STK in malignant mesothelioma. Am. J. Respir. Cell. Mol. Biol. 1998; 19: 333.
  • 107
    Smythe WR, Hwang HC, Amin KM et al. Successful treatment of experimental human mesothelioma using adenovirus transfer of the herpes simplex-thymidine kinase gene. Ann. Surg. 1995; 222: 7886.
  • 108
    Sterman  DH, Molnar-Kimber K, Iyengar T et al.  A pilot study of systemic corticosteroid administration in conjunction with intrapleural adenoviral vector administration in patients with malignant pleural mesothelioma. Cancer Gene Ther. 2000; 7: 151118.
  • 109
    Odaka M, Sterman D, Wiewrodt R et al. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy due to induction of systemic immunity. Cancer Res. 2001; 61: 620112.